| Literature DB >> 35252853 |
Guilherme Tadeu de Barcelos1, Isabel Heberle1, Juliana Cavestré Coneglian1, Bruno Allan Vieira1, Rodrigo Sudatti Delevatti1, Aline Mendes Gerage1.
Abstract
INTRODUCTION: Aerobic training of moderate intensity is the primary modality recommended in the management of hypertension. The manipulation of training variables can be an important strategy for the continuity of health benefits; however, little is known about the effects of the progression of aerobic training variables in the adaptations of blood pressure in hypertensive adults.Entities:
Keywords: aerobic exercise; cardiovascular diseases; exercise; health care; high blood pressure
Year: 2022 PMID: 35252853 PMCID: PMC8891157 DOI: 10.3389/fspor.2022.719063
Source DB: PubMed Journal: Front Sports Act Living ISSN: 2624-9367
Figure 1Flowchart with information on the different phases of the systematic review.
Characteristics of the studies.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Abdelaal and Mohamad ( | E: 20 (60%) C: 19 (53%) | 52.5 | E: 34.6 ± 1.1 C: 34.1 ± 1.2 | NR | Sedentary | Obesity and DM2 | No | No adverse events recorded |
| Baghaiee et al. ( | E: 20 (0%) C: 20 (0%) | 38.1 | E: 26.8 ± 2.1 C: 27.2 ± 1.3 | NR | Untrained | NR | No | NR |
| Farahani et al. ( | E: 12 (0%) C: 28 (0%) | 47.7 | E: 27.4 ± 4.3 C: 28.1 ± 3.5 | NR | NR | No | No | NR |
| Hagberg et al. ( | E: 10 (NR) C: NR (NR) | 64.4 | NR | NR | NR | NR | No | NR |
| Kokkinos et al. ( | E16: 18 (0%) C16: 14 (0%) E32: 20 (0%) C32: 18 (0%) | 57.5 | E16: 31.0 ± 5.5 C16: 31.0 ± 5.5 E32: 31.0 ± 4.3 C32: 31.0 ± 4.3 | NR | Sedentary | No | No | NR |
| Lamina ( | ECONT: 112 (0%) EINT: 140 (0%) C: 105 (0%) | 58.4 | ECONT: 25.0 ± 3.9 EINT: 22.5 ± 2.9 C: 24.2 ± 4.9 | > 1.0 | Sedentary | No | No | Unfavorable responses to training |
| Latosik et al. ( | E: 15 (100%) C: 10 (100%) | NR | E: 28.2± 6.3 C: 28.2 ± 5.5 | NR | NR | No | Yes | NR |
| De Meirelles et al. ( | E: 13 (61.5%) C: 6 (66.6%) | 49.5 | E: 30 ± 1 C: 32 ± 2 | NR | Sedentary | NR | No | NR |
| Soltani et al. ( | ESHORT: 10 (0%) ELONG: 10 (0%) C: 10 (0%) | 47.9 | ESHORT: 30.0 ± 2.3 ELONG: 27.3 ± 2.4 C: 29.3 ± 2.3 | NR | Untrained | NR | No | NR |
| Tanaka et al. ( | E: 12 (41.7%) C: 6 (50%) | 48.0 | NR | NR | Untrained | Obesity | No | NR |
| Turner et al. ( | E: 11 (18.2%) C: 7 (28.6%) | 66.9 | E: 30.2 ± 1.8 C: 29.6 ± 1.4 | E: 4.5 ± 2.7 | Sedentary | No | No | NR |
| Wong et al. ( | E: 52 (100%) C: 48 (100%) | 73.5 | E: 26.0 ± 2.8 C: 26.9 ± 2.9 | NR | Sedentary | NR | No | No adverse events recorded |
|
| ||||||||
| Arca et al. ( | ELAND: 19 (100%) EWATER: 19 (100%) C: 14 (100%) | 64.0 | ELAND: 28.3 ± 4.2 EWATER: 27.0 ± 5.1 C: 30.9 ± 4.8 | NR | Untrained | DM2 ( | No | NR |
| He et al. ( | E: 20 (100%) C: 22 (100%) | 57.5 | E: 27.4 ± 2.1 C: 27.7 ± 2.6 | NR | Untrained | No | No | NR |
| Hong et al. ( | E: 7 (0%) C: 7 (0%) | 51.3 | NR | NR | NR | No | No | NR |
| Khalid et al. ( | E: 12 (100%) C: 13 (100%) | 52.8 | E: 34.9 ± 3.5 C: 33.8 ± 4.1 | NR | Sedentary | Obesity | No | NR |
| Izadi et al. ( | E: 15 (46.7%) C: 15 (40%) | 61.6 | E: 25.2 ± 0.6 (Men) 25.7 ± 0.7 (Women) C: 25.2 ± 0.8 (Men) 25.3 ± 1.2 (Women) | NR | Untrained | No | No | NR |
| Koga et al. ( | E: 10 (100%) C: 5 (100%) | 49.0 | NR | NR | NR | No | No | NR |
| Maruf et al. ( | E: 45 (NR) C: 43 (NR) | 52.0 | E: 27.5 ± 5 C: 25.4 ± 4.7 | NR | NR | No | No | Knee joint pain ( |
| Miura et al. ( | E: 17 (88.2%) C: 10 (90%) | 49.0 | NR | NR | NR | No | No | NR |
| Ramos et al. ( | E: 12 (83.3%) C: 12 (83.3%) | 60.6 | E: 30.5 ± 1.5 C: 33.1 ± 2.8 | NR | NR | Obesity | No | NR |
| Tanabe et al. ( | E: 21 (52.4%) C: 10 (50%) | 48.9 | NR | NR | NR | NR | No | NR |
| Tsai et al. ( | E: 12 (41.7%) C: 11 (54.5%) | 47.9 | E: 26.1 ± 4.5 C: 25.0 ± 1.8 | NR | Untrained | No | No | NR |
| Tsai et al. ( | E: 52 (53.8%) C: 50 (54%) | 49.1 | E: 23.6 ± 1.8 C: 23.8 ± 2.2 | NR | Untrained | No | No | NR |
E, exercise group; C, control group; CONT, continuous; INT, interval; NR, not reported; BMI, body mass index; DM2, diabetes mellitus 2.
Tanaka et al. (.
Characteristics of the interventions.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| ||||||
| Abdelaal and Mohamad ( | 12 weeks | Treadmill (not defined whether walking or running) | Continuous | B: 20–35 min | 3 | B: 60–65% HRmax |
| Baghaiee et al. ( | 12 weeks | NR | Continuous | B: 25 min | 3 | B: 50% HRmax |
| Farahani et al. ( | 10 weeks | Aquatic exercise | Continuous | 35 min | 3 | B: 60–65% HRmax |
| Hagberg et al. ( | 37 weeks | Walking/running (Treadmill)/Cycle Ergometer | Continuous | 45–60 min | 3 | B: NR |
| Kokkinos et al. ( | 16 weeks | Cycle Ergometer | Continuous | 20–60 min | 3 | 60–80% HRmax |
| 32 weeks | ||||||
| Lamina ( | 8 weeks | Cycle Ergometer | Continuous | B: 45 min | NR | B: 60% HRmax |
| Interval | B: 45 min | 3 | 60–79% HRmax | |||
| Latosik et al. ( | 8 weeks | Nordic walking | Continuous | 45 min | NR | B:40–60% HRmax |
| De Meirelles et al. ( | 12 weeks | Walking/running | Continuous | 40 min | 3 | B: 75% HRmax |
| Soltani et al. ( | 8 weeks | Walking/running (Treadmill) | Interval | 27 min | 3 | B: 80% VO2 peak |
| 32 min | B: 75% VO2 peak | |||||
| Tanaka et al. ( | 10 weeks | Swimming | Continuous | B: 30 min | 3 | 60% HRres |
| Turner et al. ( | 28 weeks | Walking/running/Cycle Ergometer | Continuous | 30-50 min | 4 | B: 60–70% HRmax |
| Wong et al. ( | 20 weeks | Swimming | Continuous | B: 25–30 min | 3 to 4 | B: 60% HRmax |
|
| ||||||
| Arca et al. ( | 12 weeks | Cycle Ergometer | Continuous | 20 min | 3 | 50–60% HRres |
| Aquatic exercise | ||||||
| He et al. ( | 12 weeks | Walking | Continuous | 60 min | 3 | 45–50% VO2max |
| Hong et al. ( | 12 weeks | Walking/running (Treadmill) | Continuous | 60 min | 4 | 60% VO2max |
| Khalid et al. ( | 8 weeks | Walking (Treadmill) | Continuous | 20 min | 3 | 60–75% HRmax |
| Izadi et al. ( | 6 weeks | Cycle Ergometer | Interval | 35 min | 3 | 85–90% HRres |
| Koga et al. ( | 10 weeks | Cycle Ergometer | Continuous | 60 min | 3 | 50% VO2max |
| Maruf et al. ( | 12 weeks | Dance | Interval | 35 min | 3 | 50–70% HRres |
| Miura et al. ( | 10 weeks | Cycle Ergometer | Continuous | 60 min | 3 | 40–60% VO2max |
| Ramos et al. ( | 12 weeks | Athletics Track (not defined whether walking or running) | Continuous | 50 min | 3 | 60% HRmax/ 4–6 RPE (OMNI) |
| Tanabe et al. ( | 10 weeks | Cycle Ergometer | Continuous | 60 min | 3 | 40–60% VO2max |
| Tsai et al. ( | 12 weeks | Walking/(Treadmill) | Continuous | 30 min | 3 | 60–70% HRres |
| Tsai et al. ( | 10 weeks | Walking/running (Treadmill) | Continuous | 30 min | 3 | 60–70% HRres |
B, beginning; F, final; Min, minutes; HRmax, maximum heart rate; VO.
Risk of bias.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| Abdelaal and Mohamad ( | Low | Low | Low | Low | Low |
| Baghaiee et al. ( | Unclear | Unclear | Unclear | High | Unclear |
| Farahani et al. ( | High | Unclear | Unclear | High | Unclear |
| Hagberg et al. ( | Unclear | Unclear | Unclear | Low | Unclear |
| Kokkinos et al. ( | Unclear | Unclear | Unclear | Low | High |
| Lamina ( | Unclear | Unclear | Low | Low | High |
| Latosik et al. ( | Unclear | Unclear | Unclear | Low | High |
| De Meirelles et al. ( | Unclear | Unclear | Unclear | High | Low |
| Soltani et al. ( | Unclear | Unclear | Unclear | Low | Unclear |
| Tanaka et al. ( | Unclear | Unclear | Low | High | Unclear |
| Turner et al. ( | High | High | Unclear | Low | Unclear |
| Wong et al. ( | Low | Low | Low | Low | Low |
|
| |||||
| Arca et al. ( | Unclear | Unclear | Unclear | High | Unclear |
| He et al. ( | Unclear | Unclear | Unclear | High | High |
| Hong et al. ( | Unclear | Unclear | Unclear | High | Unclear |
| Khalid et al. ( | Low | Low | Low | Low | High |
| Izadi et al. ( | Unclear | Unclear | Unclear | Low | High |
| Koga et al. ( | Unclear | Unclear | High | High | Unclear |
| Maruf et al. ( | Low | Unclear | Unclear | Low | Low |
| Miura et al. ( | Unclear | Unclear | Unclear | Low | Unclear |
| Ramos et al. ( | Unclear | Low | Unclear | High | Unclear |
| Tanabe et al. ( | Unclear | Unclear | Unclear | High | Low |
| Tsai et al. ( | Unclear | Unclear | Unclear | Low | High |
| Tsai et al. ( | Unclear | Unclear | Low | Low | High |
Figure 2Mean differences in SBP (A) and DPB (B) observed between aerobic training with progression compared to control (without intervention). Study-specific estimates (black square); pooled estimates of random-effects meta-analyses (blue diamond). CI indicates confidence interval.
Figure 3Mean differences in SBP (A) and DBP (B) observed between aerobic training without progression compared to control (without intervention). Study-specific estimates (black square); pooled estimates of random-effects meta-analyses (blue diamond). CI indicates confidence interval.
Meta-analysis results.
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
| ||||||
|
| |||||||||
| Men | 9 | −9.89 (−17.11; −2.67) | 0.007 | 89% | <0.001 | −2.80 (−4.76; −0.85) | 0.005 | 76% | <0.001 |
| Women | 7 | −11.98 (−12.52; −11.43) | <0.001 | 0% | 0.471 | −5.81 (−9.36; −2.26) | 0.001 | 75% | <0.001 |
|
| |||||||||
| With comorbidities | 6 | −10.17 (−13.56; −6.79) | <0.001 | 41% | 0.132 | −7.76 (−11.14; −4.37) | <0.001 | 67% | 0.010 |
| Without comorbidities | 15 | −10.46 (−13.10; −7.83) | <0.001 | 28% | 0.153 | −4.59 (−6.57; −2.61) | <0.001 | 64% | <0.001 |
|
| |||||||||
| User | 10 | −10.47 (−14.63; −6.31) | <0.001 | 63% | 0.004 | −6.44 (−9.95; −2.93) | <0.001 | 80% | <0.001 |
| Non-user | 8 | −8.18 (−14.58; −1.78) | 0.012 | 99% | <0.001 | −6.45 (−11.2; −1.65) | 0.008 | 99% | <0.001 |
|
| |||||||||
| <12 weeks | 13 | −11.37 (−14.67; −8.08) | <0.001 | 34% | 0.110 | −5.04 (−7.50; −2.57) | <0.001 | 71% | <0.001 |
| 12 to 24 weeks | 12 | −10.80 (−16.01; −5.58) | <0.001 | 99% | <0.001 | −6.37 (−10.23; −2.52) | 0.001 | 99% | <0.001 |
| >24 weeks | 3 | −8.73 (−15.84; −1.62) | 0.016 | 0% | 0.546 | −6.37 (−10.81; −1.93) | 0.005 | 0% | 0.842 |
|
| |||||||||
| Continuous | 23 | −10.62 (−14.52; −6.71) | <0.001 | 99% | <0.001 | −6.10 (−8.78; −3.42) | <0.001 | 98% | <0.001 |
| Interval | 5 | −10.32 (−16.08; −4.56) | <0.001 | 48% | 0.101 | −4.62 (−6.43; −2.82) | <0.001 | 0% | 0.686 |
|
| |||||||||
| Walking/running | 11 | −11.20 (−14.61; −7.78) | <0.001 | 66% | 0.001 | −7.65 (−10.42; −4.88) | <0.001 | 81% | <0.001 |
| Cycle ergometer | 9 | −10.89 (−15.76; −6.02) | <0.001 | 51% | 0.038 | −4.01 (−6.31; −1.71) | <0.001 | 55% | 0.022 |
| Various modalities | 2 | −11.12 (−20.24; −2.01) | 0.017 | 0% | 0.466 | −7.61 (−13.74; −1.48) | 0.015 | 0% | 0.911 |
|
| |||||||||
| Dry-land | 23 | −11.06 (−13.53; −8.59) | <0.001 | 54% | 0.001 | −6.23 (−8.25; −4.22) | <0.001 | 82% | <0.001 |
| Aquatic | 4 | −12.01 (−12.56; −11.46) | <0.001 | 0% | 0.666 | −7.94 (−10.58; −5.29) | <0.001 | 15% | 0.315 |
Meta-regression results.
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Mean age (years) | 23 | −0.323 | −0.339; −0.307 | <0.001 | −0.121 | −0.337; 0.095 | 0.273 |
| Body mass index (kg/m2) | 21 | 0.192 | −0.645; 1.028 | 0.653 | −0.269 | −0.827; 0.288 | 0.344 |
| Antihypertensives users (n) | 19 | −0.028 | −0.248; 0.193 | 0.805 | 0.071 | −0.105; 0.247 | 0.428 |
| SBP basal (mmHg) | 28 | −0.234 | −0.482; 0.014 | 0.065 | - | - | - |
| DBP basal (mmHg) | 28 | - | - | - | −0.116 | −0.453; 0.220 | 0.498 |
| Weekly frequency | 26 | −1.407 | −9.057; 6.242 | 0.718 | −1.525 | −6.791; 3.741 | 0.570 |
| Weekly length (min) | 27 | 0.016 | −0.045; 0.077 | 0.604 | 0.018 | −0.022; 0.059 | 0.368 |
| Intervention period (weeks) | 28 | 0.107 | −0.295; 0.508 | 0.603 | −0.114 | −0.366; 0.138 | 0.376 |